



Centers for Disease Control
and Prevention (CDC)
National Center for Infectious Diseases
1324 Calle Cañada
San Juan, Puerto Rico 00920-3860
Tel. (787) 706-2399
FAX (787) 706-2496

Criteria for the processing of dengue samples at the CDC Dengue Branch, San Juan, Puerto Rico

The diagnosis and treatment of dengue and dengue hemorrhagic fever are guided by the symptoms and findings that the patient presents, and cannot depend on laboratory confirmation, since routine tests can not confirm dengue with the speed required for patients in critical condition. The processing of samples for serologic diagnosis takes approximately one week, and the PCR results take approximately 3 days. Even so, it is necessary to eventually have a confirmation of the diagnosis, to exclude other etiologic possibilities, and to guide the follow-up of the patient's convalescence. The CDC Dengue Branch provides dengue testing free of cost to submitting physicians, state and private laboratories.

To obtain correct data on the spread of disease, adequately decide what laboratory tests to use, correctly interpret test results, and to assure that results get to the person who requested them, the following information is indispensable:

- Complete name, age and sex of the patient
- Home address
- Date of onset of symptoms
- Date that sample was obtained
- Complete name and mailing address of the physician, laboratory, clinic or hospital that the result should be sent to.

Samples without the above-mentioned information, or written with illegible handwriting or with more than a month from date of sample collection to date of arrival at CDC, will not be analyzed.

The clinical samples that are processed weekly are of great importance to determine the serotype and genetic make-up of viruses being transmitted in the region, and to determine their geographic distribution. This information can be used to detect risk factors that may lead to a

new and more severe pattern of disease, and to refine the clinical diagnostic ability of attending physicians. Diagnostic bleeding is not provided to persons referred to CDC.

In case of a severe dengue epidemic, CDC Dengue Branch will promptly analyze samples received with the minimum above-mentioned information. If number of specimens exceeds laboratory capacity, testing may be prioritized in the following order:

- fatal cases,
- cases in intensive care,
- hospitalized cases (with thrombocytopenia, hemorrhage, shock or hemoconcentration),
- all other cases.

We want to emphasize that to maintain efficient dengue surveillance, we will continue processing samples from outpatients and mildly ill persons any time of the year, and especially when dengue incidence in the island is relatively low (usually during the months from April to July).

Case Notification and Shipment of Samples of Suspected Dengue Cases

Dengue is characterized by an acute febrile picture accompanied by headache, retroorbital pain, body pain, often a rash, and other variable symptoms that can include obvious or mild hemorrhagic manifestations (such as a petechial rash) or hemoconcentration, shock or coma. This disease should be considered whenever there is an increase in the number of persons who go to the physician with an acute febrile illness, complaints of "monga" or "influenza," or an increase in the number of clinically diagnosed cases of German measles or regular measles.

Instructions for obtaining and handling samples:

1. Once there is a clinical diagnosis of suspected dengue, take a blood sample (see #4 and #5) and fill out the Dengue Case Investigation Form (see copy attached). **With this Form you comply with the legal reporting requirement.** These forms can be obtained from the CDC Dengue Branch, the CDC Website <http://www.cdc.gov/ncidod/dybid/dengue/resources/DEN%20CASE%20Form%20Eng%20004.pdf> and also from the Regional Environmental Health Office of the Puerto Rico Department of Health. They can also be photocopied without restriction.
2. It is of great importance to fill out the Dengue Case Investigation Form in a clear and complete manner. The information received on each case (especially the date of onset of symptoms and date of sample collection) is crucial to select and interpret the laboratory analyses. Furthermore, a complete address makes it possible to identify the area where control measures should be implemented. **Samples without the above-mentioned information, or written in illegible handwriting or with more than a month from date of collection to date of arrival at CDC, will not be analyzed.**
3. The blood sample is taken in a red-top tube (preferably, but if not, you can use a green-top tube). Violet-top tubes (with heparin) should not be used. If dry ice is not available we recommend that after separating the serum, it must be maintained on ice or in a refrigerator until it is delivered to the CDC Dengue Branch. For samples from the USA or the exterior, we recommend to freeze the serum immediately after separated and to send in dry ice. The case investigation forms and the acute blood sample should reach CDC Dengue Branch as soon as possible. They can be sent through the local Environmental Health office. The acute sample can be sent immediately; there is no need to wait until the convalescent sample is taken.
4. To diagnose dengue, the laboratory requires a blood sample taken during the acute period of the disease and a second sample that can be taken from day 6 after the onset of symptoms. Informing the patient about the importance of coming back for a second sample, and giving an appointment for a specific day and hour, will increase the probability of obtaining the second sample. If the patient makes the first visit to the physician on or after day 6 after onset of the symptoms, that sample is enough. In that case, it is not necessary that the patient come for a second sample.
5. Acute-phase samples (taken on or before day 5 after onset of symptoms), will be used mainly for PCR analysis in order to detect virus. Convalescent-phase samples (taken on or after day 6 after beginning of symptoms) will be used mainly for detection of IgM anti-dengue antibodies by enzyme-linked immunosorbent assays (ELISA). Differential diagnosis for dengue and WNV

virus is available; but these tests need to be requested according to clinical presentation.

| <u>Type of sample</u> | <u>Interval since the onset of symptoms</u> | <u>Type of Analysis</u> |
|-----------------------|---|-------------------------|
| "Acute" | until day 5 | PCR |
| "Convalescent" | 6 or more days | Serology |

Samples taken on days 4 and 5 of illness are of low yield for isolation as well as serology.

WHENEVER THERE IS A HOSPITALIZED SEVERE CASE, PLEASE INDICATE IT IN THE CASE INVESTIGATION FORM.

6. Reports will be sent to the physician (if the return address has been indicated) with the results of positive, or clearly negative, cases. In cases with negative virus isolation, we will await a convalescent-phase sample before reporting a result.
7. Results will be reported only to the laboratory or the physician who sent the sample (or an authorized secretary).

Dengue Branch, CDC
1324 Calle Cañada
Puerto Nuevo
San Juan, PR 00920-3860

March 10, 2008

Tel. (787) 706-2399
Fax (787) 706-2496

Points of contact:

Dr. Muñoz ckq2@cdc.gov

Dr. Hunsperger enh4@cdc.gov

CHECK LIST FOR OBTAINING AND SHIPPING DENGUE DIAGNOSTIC SAMPLES

[] Sample

| Type of sample | Interval since date of onset of symptoms | Type of Analysis |
|----------------|---|---------------------|
| Acute | up to 5 days | PCR |
| Convalescent | 6 or more days | Serology |

[] **Form** - "Dengue Case Investigation Form"

Can be obtained from the CDC Dengue Branch in San Juan or Internet:
<http://www.cdc.gov/ncidod/dybid/dengue/resources/DEN%20CASE%20Form%20Eng%202004.pdf>

Please indicate on the sheet if the case is hospitalized. If it is a very severe case, indicate so on the "Comments" section.

Only the samples received with the information requested below, and written in a legible manner, will be analyzed:

- Complete name, age, and sex of patient
- Home address
- Date of onset of symptoms
- Date sample was obtained
- Complete name and mailing address of the physician, laboratory, clinic, or hospital

[] **Tube** - Red or green top (not violet).

[] **Labeling** - Tube and case form must agree (indicate the same name of the case).

[] **Volume** - 2 cc. (ml.) of centrifuged serum or plasma

[] **Storage** - On ice or in a refrigerator (not in a freezer) until it is delivered to the CDC Dengue Branch.

[] **Time of shipment** - Not to exceed a month after taking the sample

[] **Way of shipment** - Check with local Department of Health.

Reasons for **REJECTING** samples:

- Samples without form, form without sample
- Incomplete or illegible form – especially regarding date of onset of symptoms, date of sample collection
- Hemolyzed or frozen sample, or received more than a month after onset of illness

Dengue Branch, CDC
 1324 Calle Cañada
 Puerto Nuevo
 San Juan, PR 00920-3860

March 28, 2008

Tel. (787) 706-2399
 Fax (787) 706-2496

CDC 56.31 A REV. 11/2006 (Front)

FOR CDC DENGUE BRANCH USE ONLY

Specimen No.

S¹ _____S² _____S³ _____**SEROLOGY
LUMINEX (MIA)**

| S ¹ | | | S ² | | | S ³ | | |
|----------------|----|-------|----------------|----|-------|----------------|----|-------|
| Test Date | Ag | Titer | Test Date | Ag | Titer | Test Date | Ag | Titer |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |

IgG ELISA

| S ¹ | | | | S ² | | | | S ³ | | | |
|----------------|----|--------|-------|----------------|----|--------|-------|----------------|----|--------|-------|
| Test Date | Ag | Screen | Titer | Test Date | Ag | Screen | Titer | Test Date | Ag | Screen | Titer |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |

IgM ELISA

| S ¹ | | | S ² | | | S ³ | | |
|----------------|----|-------|----------------|----|-------|----------------|----|-------|
| Test Date | Ag | Value | Test Date | Ag | Value | Test Date | Ag | Value |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |

Neutralization

| S ¹ | | | S ² | | | S ³ | | |
|----------------|--------|-------|----------------|--------|-------|----------------|--------|-------|
| Test Date | Screen | Titer | Test Date | Screen | Titer | Test Date | Screen | Titer |
| DENV-1 | | | | | | | | |
| DENV-2 | | | | | | | | |
| DENV-3 | | | | | | | | |
| DENV-4 | | | | | | | | |
| WEST NILE | | | | | | | | |
| SLE | | | | | | | | |
| YFV | | | | | | | | |

Viral Isolation & PCR

| S ¹ | | | | S ² | | | | S ³ | | | |
|----------------|----|---------|--------|----------------|----|---------|--------|----------------|----|---------|--------|
| Test Date | ID | Isotech | IDtech | Test Date | ID | Isotech | IDtech | Test Date | ID | Isotech | IDtech |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |

Serology Lab Director Signature: _____

Virology Lab Director Signature: _____ Overall dengue interpretation: _____

This questionnaire is authorized by law (Public Health Service Act 42 USC 241). Although response to the questions asked is voluntary, cooperation of the patient is necessary for the study and control of the disease. Public reporting burden for the collection of information is estimated to average 15 minutes per response. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing the burden to PHS Reports Clearance Officer; Rm. 721-H, Humphrey Bg; 200 Independence Ave., SW; Washington, DC 20201; ATTN: PRA, and to the Office of Information and Regulatory Affairs, Office of Management and Budget, Washington, DC.